Pre-migration untagged articles

-- Kelly Lang, cfo of Merix Corp., on why the company chose Bank of America over long-time lender Wachovia Securities for a new facility.

Hundreds of companies showed up at Central Park in Manhattan last week for the JPMorgan Chase Corporate Challenge.

A medley of structures was sold over the past week, with equity-linked deals and zero coupon notes finding lots of interest. Plenty of demand came from Asia. Vanilla flows remained low, as the buoyant public market continues to sap MTN activity.

Since Fitch revised its corporate CDO methodology at the end of April it has placed 381 tranches with a notional value of $22.165bn on rating watch negative and has affirmed 134 tranches with a notional value of $15.52bn, according to RBS structured credit research.

Perhaps more so than in any other European market, the aftermath of the subprime crisis exposed with brutal clarity many of the shortcomings of the German banking industry. Philip Moore investigates what the Landesbanks are doing to protect themselves and build for a stronger and more profitable future.

Asset allocators have taken their most negative stance towards equities in a decade, with a net 27% underweight the asset class in June, according to a Merrill Lynch survey of fund managers.

The turbulence in the derivatives market surrounding the near bankruptcy of Bear Stearns gave a fillip to TriOptima, the post trade processing company.

The World Bank is selling a four year retail-targeted bond in New Zealand via Westpac, the first from a supranational borrower predominantly aimed at the country’s retail investors.

Olivant, the UK investment company led by Luqman Arnold, has increased is stake in UBS to 2.5%, using the Swiss bank’s recent Sfr16bn (£7.9bn) rights issue to become one of its biggest shareholders.

Speculation continues to swirl around Lehman Brothers.

Dealers of private EMTNs: Non-syndicated deals for less than $250m excluding financial repackaged SPVs, self-led deals and issues with a term of less than 365 days.

Deutsche Apotheker- und Ärztebank (ApoBank) failed to reach its stated ambition on Tuesday, when it was forced to price a sub-benchmark sized deal despite targeting a jumbo debut. Participants were split on whether this and other recent struggles have been caused by bad luck or bad advice.